Abstract
Cancer immunotherapy has revolutionized the field of oncology by harnessing the power of the immune system to target and eliminate cancer cells. Traditional immunotherapeutic approaches have primarily focused on activating and enhancing the activity of conventional immune cells, such as T cells and natural killer (NK) cells. However, recent advances in cancer immunotherapy have explored the use of unconventional effector cells, which possess unique characteristics and capabilities that make them attractive candidates for targeting cancer. This review aims to provide an overview about unconventional effector cells in cancer therapy, highlighting their potential advantages, challenges, and future prospects.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
